Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Digestive Diseases and Sciences
Erschienen in:

13.10.2022 | Original Article

Concomitant Diseases and Co-contribution on Progression of Liver Stiffness in Patients with Hepatitis B Virus Infection

verfasst von: Chang-Hai Liu, Wei Jiang, Dong-Bo Wu, Qing-Min Zeng, You-Juan Wang, Hong Tang

Erschienen in: Digestive Diseases and Sciences | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

The association between hepatitis B and concomitant diseases, such as fatty liver, T2DM, MetS, and Hp infection, remains unclear.

Aim

The present study was to illustrate the association and explore the co-contribution on abnormal transaminase and progression of liver stiffness.

Methods

A total of 95,998 participants underwent HBsAg screening in West China Hospital from 2014 to 2017. Multivariable logistic regression was used to determine the adjusted odds ratios.

Results

The prevalence of HBsAg-positive rate was 8.30% of our included study population. HBsAg positive was associated with negative risk of fatty liver (odds ratio [OR] 0.71, 95% confidence interval [CI] 0.65–0.78, p < 0.001) and MetS (OR 0.74, 95% CI 0.67–0.84, p < 0.001), and with positive risk of Hp infection (OR 1.09, 95% CI 1.02–1.17, p = 0.012) and T2DM (OR 1.18, 95% CI 1.01–1.40, p = 0.043). Besides, HBsAg-positive patients with T2DM had higher risk of elevated ALT (OR 2.09, 95% CI 1.69–2.83, p < 0.001 vs OR 1.59, 95% CI 1.51–1.68, p < 0.001), AST (OR 2.69, 95% CI 1.98–3.65, p < 0.001 vs OR 1.89, 95% CI 1.76–2.02, p < 0.001) than HBV alone. In addition to HBV, T2DM also can increase the risk of liver fibrosis (OR 3.23, 95% CI 1.35–7.71, p = 0.008) and cirrhosis (OR 4.31, 95% CI 1.41–13.20, p = 0.010).

Conclusion

Hepatitis B patients have a lower risk of fatty liver and MetS, and a higher risk of T2DM and Hp infection. Besides, T2DM might be possibly associated with abnormal liver transaminase and fibrosis progression in HBsAg-positive patients.
Literatur
1.
Seto WK, Lo YR, Pawlotsky JM et al. Chronic hepatitis B virus infection. Lancet 2018;392:2313–2324.PubMedCrossRef
2.
Yuen MF, Chen DS, Dusheiko GM et al. Hepatitis B virus infection. Nature Reviews Disease Primers 2018;4:18035.PubMedCrossRef
3.
Pais R, Rusu E, Zilisteanu D et al. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease. European Journal of Internal Medicine 2015;26:30–36.PubMedCrossRef
4.
Wang MM, Wang GS, Shen F et al. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors. Digestive Diseases and Sciences 2014;59:2571–2579.PubMedCrossRef
5.
Leandro G, Mangia A, Hui J et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130:1636–1642.PubMedCrossRef
6.
Peng D, Han Y, Ding H et al. Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors. Journal of Gastroenterology and Hepatology 2008;23:1082–1088.PubMedCrossRef
7.
Wong VW, Wong GL, Chu WC et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol 2012;56:533–540.PubMedCrossRef
8.
Jan CF, Chen CJ, Chiu YH et al. A population-based study investigating the association between metabolic syndrome and hepatitis B/C infection (Keelung Community-based Integrated Screening study No. 10). Int J Obes (Lond) 2006;30:794–799.PubMedCrossRef
9.
Yun JW, Cho YK, Park JH et al. Hepatic steatosis and fibrosis in young men with treatment-naïve chronic hepatitis B. Liver International : Official Journal of the International Association for the Study of the Liver 2009;29:878–883.PubMedCrossRef
10.
Li Y, Teng D, Shi X et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ 2020;369:m997.PubMedPubMedCentralCrossRef
11.
Lu J, Hou X, Tu H et al. Chronic hepatitis B virus infection status is more prevalent in patients with type 2 diabetes. Journal of Diabetes Investigation 2017;8:619–625.PubMedPubMedCentralCrossRef
12.
Han B, Liu W, Yang S et al. Association between self-monitoring of blood glucose and hepatitis B virus infection among people with diabetes mellitus: a cross-sectional study in Gansu Province, China. BMJ Open 2021;11:e048463.PubMedPubMedCentralCrossRef
13.
Schillie SF, Xing J, Murphy TV et al. Prevalence of hepatitis B virus infection among persons with diagnosed diabetes mellitus in the United States, 1999–2010. Journal of Viral Hepatitis 2012;19:674–676.PubMedCrossRef
14.
Reilly ML, Schillie SF, Smith E et al. Increased risk of acute hepatitis B among adults with diagnosed diabetes mellitus. Journal of Diabetes Science and Technology 2012;6:858–866.PubMedPubMedCentralCrossRef
15.
Li-Ng M, Tropp S, Danoff A et al. Association between chronic hepatitis B virus infection and diabetes among Asian Americans and Pacific Islanders. Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2007;39:549–556.PubMedCrossRef
16.
Whalen MB, Massidda O. Helicobacter pylori: enemy, commensal or, sometimes, friend? Journal of Infection in Developing Countries 2015;9:674–678.PubMedCrossRef
17.
Tan HJ, Goh KL. Extragastrointestinal manifestations of Helicobacter pylori infection: facts or myth? A critical review. Journal of Digestive Diseases 2012;13:342–349.PubMedCrossRef
18.
Waluga M, Kukla M, Żorniak M et al. From the stomach to other organs: Helicobacter pylori and the liver. World Journal of Hepatology 2015;7:2136–2146.PubMedPubMedCentralCrossRef
19.
Fan XG, Zou YY, Wu AH et al. Seroprevalence of Helicobacter pylori infection in patients with hepatitis B. British Journal of Biomedical Science 1998;55:176–178.PubMed
20.
Ponzetto A, Pellicano R, Leone N et al. Helicobacter pylori seroprevalence in cirrhotic patients with hepatitis B virus infection. The Netherlands Journal of Medicine 2000;56:206–210.PubMedCrossRef
21.
Nandakumar R, Naik AS, Pandit B et al. Effect of Helicobacter pylori eradication on serum ammonia levels in patients with chronic liver disease. Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology 2003;22:221–223.PubMed
22.
Abu Al-Soud W, Stenram U, Ljungh A et al. DNA of Helicobacter spp. and common gut bacteria in primary liver carcinoma. Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2008;40:126–131.PubMedCrossRef
23.
Wang J, Chen RC, Zheng YX et al. Helicobacter pylori infection may increase the risk of progression of chronic hepatitis B disease among the Chinese population: a meta-analysis. Int J Infect Dis 2016;50:30–37.PubMedCrossRef
24.
Luo W, Wu S, Chen H et al. Thyroid dysfunction is associated with the loss of hepatitis B surface antigen in patients with chronic hepatitis B undergoing treatment with α-interferon. The Journal of International Medical Research 2021;49:3000605211025139.PubMedCrossRef
25.
Yeo YH, Ho HJ, Yang HI et al. Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. Gastroenterology 2019;156:635-646.e639.PubMedCrossRef
26.
McPherson S, Hardy T, Henderson E et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. Journal of Hepatology 2015;62:1148–1155.PubMedCrossRef
27.
Ekstedt M, Hagström H, Nasr P et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology (Baltimore, Md) 2015;61:1547–1554.PubMedCrossRef
28.
Wang C, Wang X, Gong G et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. International Journal of Cancer 2012;130:1639–1648.PubMedCrossRef
29.
Campbell PT, Newton CC, Freedman ND et al. Body Mass Index, Waist Circumference, Diabetes, and Risk of Liver Cancer for U.S. Adults. Cancer Research 2016;76:6076–6083.PubMedPubMedCentralCrossRef
30.
El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460–468.PubMedCrossRef
31.
Wong GL, Wong VW, Choi PC et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 2009;58:111–117.PubMedCrossRef
32.
Lesmana LA, Lesmana CR, Pakasi LS et al. Prevalence of hepatic steatosis in chronic hepatitis B patients and its association with disease severity. Acta Med Indones 2012;44:35–39.PubMed
33.
Shi JP, Fan JG, Wu R et al. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. J Gastroenterol Hepatol 2008;23:1419–1425.PubMedCrossRef
34.
Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet (London, England). 2004;363:157–163.
35.
Saadeh S, Younossi ZM, Remer EM et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745–750.PubMedCrossRef
36.
Seto WK, Hui RWH, Mak LY et al. Association Between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B. Clin Gastroenterol Hepatol 2018;16:575-583.e572.PubMedCrossRef
37.
Karlas T, Petroff D, Sasso M et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol 2017;66:1022–1030.PubMedCrossRef
38.
Dietrich CF, Bamber J, Berzigotti A et al. EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version). Ultraschall Med 2017;38:e16–e47.PubMedCrossRef
39.
EASL-ALEH Clinical Practice Guidelines. Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015;63:237–264.CrossRef
40.
Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol 2017;67:862–873.PubMedCrossRef
41.
Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640–1645.PubMedCrossRef
42.
Executive summary: Standards of medical care in diabetes—2014. Diabetes Care. 2014;37:S5–13.
43.
Klein PD, Malaty HM, Martin RF et al. Noninvasive detection of Helicobacter pylori infection in clinical practice: the 13C urea breath test. Am J Gastroenterol 1996;91:690–694.PubMed
44.
45.
Joo EJ, Chang Y, Yeom JS et al. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study. Hepatology 2017;65:828–835.PubMedCrossRef
46.
Zhong GC, Wu YL, Hao FB et al. Current but not past hepatitis B virus infection is associated with a decreased risk of nonalcoholic fatty liver disease in the Chinese population: A case-control study with propensity score analysis. J Viral Hepat 2018;25:842–852.PubMedCrossRef
47.
48.
Suliman I, Abdelgelil N, Kassamali F et al. The Effects of Hepatic Steatosis on the Natural History of HBV Infection. Clin Liver Dis 2019;23:433–450.PubMedCrossRef
49.
50.
Wang CC, Cheng PN, Kao JH. Systematic review: chronic viral hepatitis and metabolic derangement. Aliment Pharmacol Ther 2020;51:216–230.PubMedCrossRef
51.
Wang CC, Hsu CS, Liu CJ et al. Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. Journal of Gastroenterology and Hepatology 2008;23:779–782.PubMedCrossRef
52.
Huang ZS, Huang TS, Wu TH et al. Asymptomatic chronic hepatitis B virus infection does not increase the risk of diabetes mellitus: a ten-year observation. J Gastroenterol Hepatol 2010;25:1420–1425.PubMedCrossRef
53.
Mohamed AA, Elshimy AA, El Sadik AO et al. Association between Severity of Liver Disease, Frequency of Helicobacter pylori Infection, and Degree of Gastric Lesion in Egyptian Patients with Hepatitis B Virus Infection. Am J Trop Med Hyg 2018;98:221–226.PubMedCrossRef
54.
Huang J, Cui J. Evaluation of Helicobacter pylori Infection in Patients with Chronic Hepatic Disease. Chin Med J (Engl) 2017;130:149–154.PubMed
55.
Wang MY, Yue JY, Zhang YX et al. Helicobacter pylori infection in asymptomatic HBV carriers, alcohol users and normal adult population in Shandong Province, China. Clinics and Research in Hepatology and Gastroenterology 2011;35:560–562.PubMedCrossRef
56.
Zheng RD, Chen JN, Zhuang QY et al. Clinical and virological characteristics of chronic hepatitis B patients with hepatic steatosis. Int J Med Sci 2013;10:641–646.PubMedPubMedCentralCrossRef
57.
Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol 2011;26:1361–1367.PubMed
58.
Hsieh PS, Hsieh YJ. Impact of liver diseases on the development of type 2 diabetes mellitus. World Journal of Gastroenterology 2011;17:5240–5245.PubMedPubMedCentralCrossRef
59.
Holstein A, Hinze S, Thiessen E et al. Clinical implications of hepatogenous diabetes in liver cirrhosis. Journal of Gastroenterology and Hepatology 2002;17:677–681.PubMedCrossRef
60.
Lee YB, Ha Y, Chon YE et al. Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B. Clin Mol Hepatol 2019;25:52–64.PubMedCrossRef
61.
Pang Y, Kartsonaki C, Turnbull I et al. Diabetes, Plasma Glucose, and Incidence of Fatty Liver, Cirrhosis, and Liver Cancer: A Prospective Study of 0.5 Million People. Hepatology 2018;68:1308–1318.PubMedCrossRef
62.
Ahmadieh H, Azar ST. Liver disease and diabetes: association, pathophysiology, and management. Diabetes Research and Clinical Practice 2014;104:53–62.PubMedCrossRef
Metadaten
Titel
Concomitant Diseases and Co-contribution on Progression of Liver Stiffness in Patients with Hepatitis B Virus Infection
verfasst von
Chang-Hai Liu
Wei Jiang
Dong-Bo Wu
Qing-Min Zeng
You-Juan Wang
Hong Tang
Publikationsdatum
13.10.2022
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 4/2023
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-022-07695-2

Weitere Artikel der Ausgabe 4/2023

“M1/M2” Muscularis Macrophages Are Associated with Reduction of Interstitial Cells of Cajal and Glial Cells in Achalasia

  • Open Access
  • Original Article

Muscle Mass Effect: The Importance of Diagnosing and Treating Sarcopenia in Patients with Advanced Chronic Liver Disease

  • Invited Commentary

Nintedanib Induces the Autophagy-Dependent Death of Gastric Cancer Cells by Inhibiting the STAT3/Beclin1 Pathway

  • Original Article

Electronic Health Record Work Demands for Gastroenterology and Hepatology Providers: A Prospective Use Analysis and Survey Study

  • Original Article

P-element-Induced Wimpy-Testis-Like Protein 1 Regulates the Activation of Pancreatic Stellate Cells Through the PI3K/AKT/mTOR Signaling Pathway

  • Original Article

Endoscopic Ultrasound-Directed Transgastric ERCP (EDGE) Utilization of Trends Among Interventional Endoscopists

  • Original Article

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Nierenzellkarzinom: Kein Nachteil durch subkutan appliziertes Nivolumab

Die subkutane Applikation von Nivolumab ist nach Daten einer Phase-3-Studie ähnlich gut wirksam wie die intravenöse: Die Pharmakokinetik ist vergleichbar, die objektive Response war in der Studie sogar leicht besser als in der Gruppe mit Infusionen.

Vorteile für Androgenentzug plus Androgenrezeptorblockade

Für Männer mit metastasiertem hormonsensitivem Prostata-Ca. (mHSPC), die keine Hormonchemotherapie wollen oder vertragen, ist der Androgenentzug plus Darolutamid eine Alternative: Das Progressionsrisiko wird im Vergleich zum alleinigen Androgenentzug fast halbiert.

Mit Lidocain kommt der Darm nicht schneller in Schwung

Verzögertes Wiederanspringen der Darmfunktion ist ein Hauptfaktor dafür, wenn Patientinnen und Patienten nach einer Kolonresektion länger als geplant im Krankenhaus bleiben müssen. Ob man diesem Problem mit Lidocain vorbeugen kann, war Thema einer Studie.

Koronare Herzkrankheit: Das waren die Top-Studien 2024

Zum Thema Koronare Herzkrankheit gab es 2024 wichtige neue Studien. Beleuchtet wurden darin unter anderem der Stellenwert von Betablockern nach Herzinfarkt, neue Optionen für eine Lipidsenkung sowie die Therapie bei infarktbedingtem kardiogenem Schock.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise